Squarepoint Ops LLC Takes Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Squarepoint Ops LLC purchased a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 29,499 shares of the biotechnology company's stock, valued at approximately $718,000. Squarepoint Ops LLC owned about 0.11% of Arcturus Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. bought a new stake in Arcturus Therapeutics during the first quarter valued at about $40,000. Quest Partners LLC lifted its stake in shares of Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock valued at $90,000 after buying an additional 3,579 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock worth $152,000 after acquiring an additional 428 shares during the period. Public Employees Retirement System of Ohio boosted its stake in Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company's stock worth $156,000 after purchasing an additional 1,800 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Arcturus Therapeutics by 66.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 5,153 shares of the biotechnology company's stock valued at $174,000 after buying an additional 2,064 shares during the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ARCT has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partners started coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They issued an "outperform" rating and a $70.00 target price on the stock. Leerink Partnrs raised shares of Arcturus Therapeutics to a "strong-buy" rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $71.40.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock traded down $1.40 during trading on Tuesday, hitting $22.47. The stock had a trading volume of 212,364 shares, compared to its average volume of 484,275. The stock has a market cap of $605.16 million, a PE ratio of -5.75 and a beta of 2.61. Arcturus Therapeutics Holdings Inc. has a 12 month low of $17.52 and a 12 month high of $45.00. The firm's fifty day simple moving average is $21.00 and its 200-day simple moving average is $26.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.85) by $1.21. The business had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. During the same quarter last year, the firm earned ($1.98) earnings per share. Analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.